Search Results - t+cell+receptor

14 Results Sort By:
T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy
Summary: The NCI seeks parties interested in research co-development and/or licensing this library of TCRs targeting CDKN2A mutations. Description of Technology: Cyclin-dependent kinase inhibitor 2A gene, also known as CDKN2A, is a tumor suppressor gene and is commonly inactivated through somatic mutations in many human cancers. For example, inactivation...
Published: 4/23/2026   |   Updated: 8/2/2023   |   Inventor(s): Sri Krishna, Shoshana Levi, Paul Robbins, Steven Rosenberg, Shirley Nah, Rami Yoseph, Frank Lowery
Keywords(s): adoptive cell therapy, CDKN2A, cyclin dependent kinase inhibitor 2A, Immunotherapy, Krishna, MELANOMA, Neoantigen, Rosenberg, T Cell Receptor, TCR
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration
T cell Receptors Which Recognize Mutated EGFR
Abstract: Epidermal growth factor receptor (EGFR) is a transmembrane protein involved in cell growth and proliferation. Mutations in this protein can lead to overexpression, causing several types of cancer; notably, non-small cell lung cancer (NSCLC). For example, mutations in EGFR are found in up to 50% of NSCLC patients and the E746-A750 deletion...
Published: 4/22/2025   |   Updated: 8/2/2023   |   Inventor(s): Kenichi Hanada, Chihao Zhao, Anna Pasetto, James Yang
Keywords(s): EGFR mutation, Epidermal Growth Factor Receptor, Hanada, Immunotherapy, T Cell Receptor, TCR
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Collaboration
Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)
Summary: NCI seeks commercial partners to co-develop and/or license a novel method to identify neoantigen reactive T cells and TCRs. Description of Technology: Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize unique antigens expressed by cancer cells (“neoantigens”). Neoantigen specific TIL administration...
Published: 4/24/2026   |   Updated: 8/2/2023   |   Inventor(s): Sri Krishna, Paul Robbins, Rami Yoseph, James Yang, Kenichi Hanada, Frank Lowery, Steven Rosenberg
Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptor, TCR, TIL, tumor, Tumor Infiltrating Lymphocyte
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain
Summary: Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking licensing and/or collaboration partners to develop therapeutic cell populations arising out of these technologies. An ideal partner would enter into both a Cooperative Research and Development Agreement (CRADA)...
Published: 4/23/2026   |   Updated: 8/2/2023   |   Inventor(s): Paul Love, Guillaume Gaud, Christian Hinrichs, John Davies
Keywords(s): CD3, Davies, Eunice Kennedy Shriver National Institute of Child Health an, Gaud, Hinrichs, Immuno-receptor Tyrosine-based Activation Motif, Immunotherapy, ITAM, Love, National Cancer Institute, Nci, NICHD, T Cell Receptor, TCR, Zeta Chain
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology
T Cell Receptors Targeting p53 Mutations for Cancer Immunotherapy and Adoptive Cell Therapy
Abstract: The tumor protein p53 is a cell cycle regulator. It responds to DNA damage by triggering the DNA repair pathway and allowing cell division to occur or inducing cell growth arrest, cellular senescence, and/or apoptosis. p53 therefore acts as a tumor suppressor by preventing uncontrolled cell division. However, mutations in p53 that impair...
Published: 4/22/2025   |   Updated: 8/2/2023   |   Inventor(s): Drew Deniger, Parisa Malekzadeh, Winifred Lo, Rami Yoseph, Paul Robbins, Maria Parkhurst, Anna Pasetto, Yong-Chen Lu, Steven Rosenberg
Keywords(s): Immunotherapy, p53, Rosenberg, T Cell Receptor, TCR, Tumor Protein P53
Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology
Inhibition of T Cell Differentiation and Senescence by Overexpression of Transcription Factor c-Myb
Abstract: Adoptive Cell Therapy (ACT) is a promising technique that uses a patient's own T cells to treat cancer. The process requires removing and engineering a patient's T cells to express a chimeric antigen receptor (CAR) or T cell receptor (TCR) that targets a specific cancer antigen. When the modified T cells are reintroduced into the patient,...
Published: 4/22/2025   |   Updated: 8/2/2023   |   Inventor(s): Sanjivan Gautam, Yun Ji, Luca Gattinoni
Keywords(s): act, Adoptive Cell Transfer, CANCER, CAR, chimeric antigen receptor, Gattinoni, Immunotherapy, Infectious Disease, Stem Cell, T cell, T Cell Receptor, TCR
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing
Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs)
Summary: The NCI seeks parties interested in licensing this library of cell lines stably expressing tumor-specific antigens and HLAs. Description of Technology: Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy that utilizes tumor infiltrating lymphocytes (TILs) or genetically engineered T cells to attack tumor cells through...
Published: 4/23/2026   |   Updated: 8/2/2023   |   Inventor(s):  
Keywords(s): act, adoptive cell therapy, Antigen Presenting Cells, APC, cell lines, HLA, Human Leukocyte Antigen, Immunotherapy, KRAS, Levin, p53, Rosenberg, T Cell Receptor, TCR, TIL, Tumor Infiltrating Lymphocytes, Tumor-Specific Antigen
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Research Materials, TherapeuticArea > Infectious Disease
Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes
Description of Technology: Human papillomavirus (HPV) has been linked to many cancers including cervix, uterine, anus, vulva, vagina, and penis. Although HPV vaccines exist to prevent HPV-associated cancers, there are still more than 5,000 deaths caused by HPV-associated cancers each year in the US and cervical cancer continues to be the second leading...
Published: 4/16/2026   |   Updated: 8/2/2023   |   Inventor(s): Mitchell Ho, Zhijian Duan, Christian Hinrichs
Keywords(s): adoptive cell therapy, HO, HPV16, Immunotherapy, NANOBODY, T Cell Receptor
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy
Summary: The NCI seeks parties interested in research co-development and/or licensing of these HLA-A*0301 restricted TCRs that target the BRAF V600E mutation. Description of Technology: BRAF is an oncogene that encodinges a serine-threonine kinase (B-Raf kinase) important in regulating cell growth and differentiation. Spontaneous mutations in the...
Published: 4/23/2026   |   Updated: 8/2/2023   |   Inventor(s): Zhiya Yu, Catherine Ade, Matthew Sporn, James Yang, Kenichi Hanada
Keywords(s): BRAF, B-Raf kinase, B-Raf Proto-Oncogene, HLA-A*0301 restriction, Immunotherapy, Rosenberg, serine-threonine kinase, T Cell Receptor, T cell therapy, TCR, V600E mutation, Yang, Yu
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing
T-cell Receptor Targeting Human Papillomavirus-16 E7 Oncoprotein
Summary: The NCI Center for Immuno-Oncology is actively seeking co-development partners and/or licensees for this E7-targeting TCR with therapeutic potential for HPV-positive conditions. Description of Technology: Human papillomavirus (HPV) is a group of human viruses known to cause various malignancies. Of the group, HPV-16 is the most prevalent...
Published: 4/23/2026   |   Updated: 8/2/2023   |   Inventor(s): Christian Hinrichs, Steven Rosenberg
Keywords(s): act, adoptive cell therapy, Cervical cancer, E7, HLA-A*02, HPV, Human Papillomavirus, Major Histocompatibility Complex, MALIGNANCY, MHC, ONCOPROTEIN, Rosenberg, T Cell Receptor, TCR
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease
1 2